Galapagos NV (NASDAQ:GLPG)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a note issued to investors on Sunday. They currently have a $120.00 target price on the biotechnology company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 23.49% from the company’s previous close.
Other equities research analysts also recently issued research reports about the company. Morgan Stanley reaffirmed an “overweight” rating and set a $92.00 target price on shares of Galapagos NV in a report on Thursday, August 10th. Janney Montgomery Scott raised Galapagos NV from a “sell” rating to a “neutral” rating in a report on Friday, July 7th. They noted that the move was a valuation call. Cowen and Company reaffirmed a “buy” rating on shares of Galapagos NV in a report on Thursday, August 10th. BidaskClub raised Galapagos NV from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Finally, Nomura lifted their target price on Galapagos NV from $108.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, August 11th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $108.14.
Shares of Galapagos NV (NASDAQ:GLPG) opened at 97.17 on Friday. Galapagos NV has a 52-week low of $57.16 and a 52-week high of $104.12. The stock’s market cap is $4.94 billion. The stock’s 50 day moving average is $101.06 and its 200 day moving average is $101.06.
COPYRIGHT VIOLATION NOTICE: “Galapagos NV (GLPG) Earns “Buy” Rating from Stifel Nicolaus” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/10/29/galapagos-nv-glpg-earns-buy-rating-from-stifel-nicolaus.html.
A number of large investors have recently made changes to their positions in the business. Aperio Group LLC lifted its holdings in Galapagos NV by 22.2% in the third quarter. Aperio Group LLC now owns 4,159 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 755 shares during the period. Eqis Capital Management Inc. lifted its holdings in Galapagos NV by 17.8% in the third quarter. Eqis Capital Management Inc. now owns 12,192 shares of the biotechnology company’s stock valued at $1,241,000 after acquiring an additional 1,846 shares during the period. Cookson Peirce & Co. Inc. lifted its holdings in Galapagos NV by 0.7% in the second quarter. Cookson Peirce & Co. Inc. now owns 3,045 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 20 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Galapagos NV in the second quarter valued at approximately $214,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Galapagos NV in the second quarter valued at approximately $704,000. 23.62% of the stock is owned by institutional investors.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
What are top analysts saying about Galapagos NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galapagos NV and related companies.